How Vyleesi Works for HSDD
Vyleesi (bremelanotide) treats hypoactive sexual desire disorder (HSDD) in premenopausal women by activating melanocortin receptors in the brain. These receptors, particularly MC4R, influence sexual arousal pathways, increasing desire without relying on hormones like estrogen or testosterone. Administered as a subcutaneous injection into the abdomen or thigh 45 minutes before anticipated sexual activity, it boosts central nervous system signals for spontaneous desire, addressing the chronic lack of motivation that defines HSDD.[1][2]
What Is HSDD and Why Target Melanocortin Receptors?
HSDD involves low sexual desire causing personal distress, not due to other medical issues or relationship problems. Traditional treatments like Addyi (flibanserin) modulate serotonin, but Vyleesi targets melanocortin-4 receptors (MC4R) in the hypothalamus and limbic system—areas linked to sexual motivation in animal and human studies. This pathway enhances dopamine release and reduces inhibition, mimicking natural arousal cues without daily dosing.[1][3]
Dosage, Timing, and Administration
Users self-inject 1.75 mg under the skin at least 45 minutes before sex, using a prefilled autoinjector. Limit to one dose per 24 hours and no more than eight per month to minimize side effects. It peaks in blood levels within 1 hour and lasts 24-72 hours, but effects are activity-timed, not continuous.[2][4]
Clinical Evidence from Trials
In two Phase 3 trials (RECONNECT studies, n=1,267 premenopausal women), Vyleesi increased satisfying sexual events by 0.3-0.5 per month versus placebo, with 35-60% of users reporting desire improvements on validated scales like FSFI. FDA approval in 2019 was based on these, showing statistical significance (p<0.01) despite modest absolute gains.[1][5]
Common Side Effects and Risks
Nausea affects 40% of users (often first dose, mitigated by anti-nausea meds), plus flushing (20%), headache (12%), and injection-site reactions. Rare risks include blood pressure spikes (monitor in hypertension patients) and skin darkening. Not for postmenopausal women, breastfeeding, or those with liver/kidney issues.[2][4]
How Vyleesi Compares to Addyi
Unlike daily oral Addyi, which lowers serotonin to raise desire but risks alcohol interactions and sedation, Vyleesi is on-demand and melanocortin-based. Addyi suits broader use but has black-box warnings; Vyleesi avoids daily commitment but causes more acute nausea. Neither cures HSDD—therapy often pairs with either.[3][5]
Who Makes Vyleesi and Availability
Palatin Technologies developed it; AMAG (now Viatris) marketed initially. Available by prescription in the US since 2019, priced at $1,300-$2,000 for four autoinjectors (insurance varies). No generic yet; check DrugPatentWatch.com for patent status.[6][7]
[1]: FDA Label - Vyleesi (bremelanotide) prescribing information, fda.gov
[2]: AMAG Pharmaceuticals (Vyleesi HCP site), vyleesi.com
[3]: Journal of Sexual Medicine (2019) - Bremelanotide mechanism review
[4]: Clinical Pharmacology & Therapeutics (2020) - PK/PD data
[5]: NEJM (2019) - RECONNECT trial results
[6]: Drugs.com - Vyleesi overview
[7]: DrugPatentWatch.com - Bremelanotide patents